Eli Lilly announced its acquisition of AtaiBeckley, a psychedelic drugmaker, for $2.8 billion, which includes an upfront payment of $6.75 per share, representing a 26% premium over AtaiBeckley's recent closing price.
This deal grants Lilly access to AtaiBeckley's lead drug, BPL-003, a DMT-based treatment currently in Phase 3 trials for treatment-resistant depression, with initial results expected in 2029. Additionally, AtaiBeckley is developing other psychedelics, including a drug related to MDMA.
The acquisition reflects a broader trend in the pharmaceutical industry towards exploring psychedelic treatments, supported by recent governmental initiatives. Lilly's aggressive acquisition strategy this year, which may total up to $25 billion across eight deals, indicates its commitment to expanding its portfolio in high-potential areas.
Following the announcement, AtaiBeckley shares surged over 30% in premarket trading, underscoring investor optimism about the future of psychedelic therapies